Exenatide, an incretin mimetic, was approved by the Food and Drug Administration (FDA) on April 28, 2005, as adjunctive therapy to improve glycemic control in patients with type 2 diabetes ...

The FDA approved exenatide in April 2005 and it was the first incretin mimetic to hit the market. Exenatide (Byetta, Amylin) is synthetic exendin-4, which binds to and activates the pancreatic ...

The exenatide dose was 5 mcg twice daily for four weeks, then 10 mcg twice daily. The insulin was titrated to achieve glucose control (fasting glucose <126 mg/dL and postprandial <180 mg/dL).

Exenatide is the active ingredient in BYETTA (R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

Treatment with the diabetes drug exenatide was associated with a significant decrease in hyperglycemia in acute stroke patients, a new study shows. The research could offer clinicians an ...

Exenatide, the synthetic agonist of the GLP-1 receptor, has neurotrophic and neuroprotective properties in vitro. 32 Mechanisms underlying these properties are still not completely understood.

Exenatide was associated with a small but statistically significant decrease in BMI, and waist circumference decreased by 1.68 cm (Table 2). There was no change in body composition using BIA.

In the exenatide-PD trial, a randomized, placebo-controlled clinical trial in patients with moderate-stage PD, the GLP-1 receptor agonist exenatide showed positive effects on the motor severity of ...

Exenatide, a glucagon-like peptide-1 agonist (GLP-1 agonist) medication marketed as Byetta® and Bydureon® and used in the treatment of insulin resistance in patients with Type 2 diabetes, has been ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...

Exenatide did not lead to QT prolongation, even at very high concentrations in the blood," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals.